Company intelligence / Profile preview
Human Life CORD
Chiyoda City, Tokyo, Japanhumanlifecord.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Currently conducting clinical trials for umbilical cord-derived mesenchymal stromal cells therapy for COVID-19 related Acute Respiratory Distress Syndrome. One trial is recruiting (JPRN-JapicCTI-205465) and one is completed (JPRN-jRCT1080225369).
- Therapeutic areas
- PulmonologyRare Diseases
- Modalities
- Cell TherapyMesenchymal Stromal Cells (MSCs)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Tissue GenesisNYBCe (New York Blood Center enterprises)
Beyond the preview
Go deeper on Human Life CORD.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Human Life CORD.